3oxz
From Proteopedia
(Difference between revisions)
m (Protected "3oxz" [edit=sysop:move=sysop]) |
|||
Line 1: | Line 1: | ||
- | + | ==Crystal structure of ABL kinase domain bound with a DFG-out inhibitor AP24534== | |
- | + | <StructureSection load='3oxz' size='340' side='right' caption='[[3oxz]], [[Resolution|resolution]] 2.20Å' scene=''> | |
- | { | + | == Structural highlights == |
+ | <table><tr><td colspan='2'>[[3oxz]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Mus_musculus Mus musculus]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3OXZ OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3OXZ FirstGlance]. <br> | ||
+ | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=0LI:3-(IMIDAZO[1,2-B]PYRIDAZIN-3-YLETHYNYL)-4-METHYL-N-{4-[(4-METHYLPIPERAZIN-1-YL)METHYL]-3-(TRIFLUOROMETHYL)PHENYL}BENZAMIDE'>0LI</scene></td></tr> | ||
+ | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[3ik3|3ik3]], [[3oy3|3oy3]]</td></tr> | ||
+ | <tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">Abl1, Abl ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=10090 Mus musculus])</td></tr> | ||
+ | <tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Non-specific_protein-tyrosine_kinase Non-specific protein-tyrosine kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.10.2 2.7.10.2] </span></td></tr> | ||
+ | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3oxz FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3oxz OCA], [http://www.rcsb.org/pdb/explore.do?structureId=3oxz RCSB], [http://www.ebi.ac.uk/pdbsum/3oxz PDBsum]</span></td></tr> | ||
+ | </table> | ||
+ | <div style="background-color:#fffaf0;"> | ||
+ | == Publication Abstract from PubMed == | ||
+ | The BCR-ABL inhibitor imatinib has revolutionized the treatment of chronic myeloid leukemia. However, drug resistance caused by kinase domain mutations has necessitated the development of new mutation-resistant inhibitors, most recently against the T315I gatekeeper residue mutation. Ponatinib (AP24534) inhibits both native and mutant BCR-ABL, including T315I, acting as a pan-BCR-ABL inhibitor. Here, we undertook a combined crystallographic and structure-activity relationship analysis on ponatinib to understand this unique profile. While the ethynyl linker is a key inhibitor functionality that interacts with the gatekeeper, virtually all other components of ponatinib play an essential role in its T315I inhibitory activity. The extensive network of optimized molecular contacts found in the DFG-out binding mode leads to high potency and renders binding less susceptible to disruption by single point mutations. The inhibitory mechanism exemplified by ponatinib may have broad relevance to designing inhibitors against other kinases with mutated gatekeeper residues. | ||
- | + | Structural Mechanism of the Pan-BCR-ABL Inhibitor Ponatinib (AP24534): Lessons for Overcoming Kinase Inhibitor Resistance.,Zhou T, Commodore L, Huang WS, Wang Y, Thomas M, Keats J, Xu Q, Rivera VM, Shakespeare WC, Clackson T, Dalgarno DC, Zhu X Chem Biol Drug Des. 2011 Jan;77(1):1-11. doi:, 10.1111/j.1747-0285.2010.01054.x. Epub 2010 Nov 30. PMID:21118377<ref>PMID:21118377</ref> | |
- | + | ||
- | + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |
- | + | </div> | |
- | == | + | ==See Also== |
- | + | *[[Tyrosine kinase|Tyrosine kinase]] | |
+ | == References == | ||
+ | <references/> | ||
+ | __TOC__ | ||
+ | </StructureSection> | ||
[[Category: Mus musculus]] | [[Category: Mus musculus]] | ||
[[Category: Non-specific protein-tyrosine kinase]] | [[Category: Non-specific protein-tyrosine kinase]] | ||
- | [[Category: Clackson, T | + | [[Category: Clackson, T]] |
- | [[Category: Dalgarno, D C | + | [[Category: Dalgarno, D C]] |
- | [[Category: Huang, W S | + | [[Category: Huang, W S]] |
- | [[Category: Keats, J | + | [[Category: Keats, J]] |
- | [[Category: Rivera, V | + | [[Category: Rivera, V]] |
- | [[Category: Shakespeare, W C | + | [[Category: Shakespeare, W C]] |
- | [[Category: Thomas, M | + | [[Category: Thomas, M]] |
- | [[Category: Wang, Y | + | [[Category: Wang, Y]] |
- | [[Category: Xu, Q | + | [[Category: Xu, Q]] |
- | [[Category: Zhou, T | + | [[Category: Zhou, T]] |
- | [[Category: Zhu, X | + | [[Category: Zhu, X]] |
[[Category: Atp binding]] | [[Category: Atp binding]] | ||
[[Category: Phosphorylation]] | [[Category: Phosphorylation]] |
Revision as of 07:21, 19 December 2014
Crystal structure of ABL kinase domain bound with a DFG-out inhibitor AP24534
|
Categories: Mus musculus | Non-specific protein-tyrosine kinase | Clackson, T | Dalgarno, D C | Huang, W S | Keats, J | Rivera, V | Shakespeare, W C | Thomas, M | Wang, Y | Xu, Q | Zhou, T | Zhu, X | Atp binding | Phosphorylation | Phosphotransferase | Protein kinase two-domain fold | Protein-inhibitor complex | Transferase-transferase inhibitor complex